Opendata, web and dolomites

PET-AlphaSy SIGNED

PET Imaging of Alpha-Synuclein Fibril Formation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PET-AlphaSy project word cloud

Explore the words cloud of the PET-AlphaSy project. It provides you a very rough idea of what is the project "PET-AlphaSy" about.

fashion    medicine    until    rely    pharmaceutical    pet    trial    scientific    spanning    too    start    drug    thought    alpha    parkinson    tomography    positron    presently    diagnosis    validated    unmet    goals    rate    insufficient    diagnose    pharmacy    treatment    ineffective    healthcare    pd    ways    aid    medicinal    apparent    situation    interdisciplinary    synuclein    probes    successful    training    visualization    enterprises    chemistry    stage    protein    radiopharmaceutical    patient    tracers    market    entrepreneurial    personalized    skills    gmp    aggregates    tailoring    pathogenic    techniques    train    individual    critical    academic    radioisotope    stages    industry    error    physicians    frontline    favorable    fibril    effectiveness    treatments    generation    expensive    respect    disease    diseases    modifying    time    scientists    pathology    emission    tracer    molecular    imaging    hallmark    limiting    biology    nuclear    leads    strategy    reduce    assembled   

Project "PET-AlphaSy" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 4˙100˙370 €
 EC max contribution 4˙100˙370 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 892˙566.00
2    STICHTING VUMC NL (AMSTERDAM) participant 796˙859.00
3    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 758˙365.00
4    UPPSALA UNIVERSITET SE (UPPSALA) participant 563˙965.00
5    REGION HOVEDSTADEN DK (HILLEROD) participant 297˙522.00
6    BIOARCTIC AB SE (STOCKHOLM) participant 281˙982.00
7    ELYSIA BE (LIEGE) participant 256˙320.00
8    JOHANNES GUTENBERG-UNIVERSITAT MAINZ DE (MAINZ) participant 252˙788.00
9    Eckert & Ziegler Eurotope GmbH DE (Berlin) partner 0.00
10    H. LUNDBECK AS DK (VALBY) partner 0.00
11    ION BEAM APPLICATIONS SA BE (OTTIGNIES LOUVAIN LA NEUVE) partner 0.00
12    NOVO NORDISK A/S DK (BAGSVAERD) partner 0.00
13    PMOD TECHNOLOGIES GMBH CH (ADLISWIL) partner 0.00
14    POSITRONPHARMA SA CL (SANTIAGO) partner 0.00
15    TAGWORKS PHARMACEUTICALS BV NL (Eindhoven) partner 0.00
16    UNIVERSITE DE LIEGE BE (LIEGE) partner 0.00

Map

 Project objective

Too often, physicians have to rely on a trial and error strategy until the most effective treatment for an individual patient is identified. This leads to a critical loss of time, making the healthcare system ineffective and expensive. In respect to drug development, a high failure rate is apparent at all stages of development and ways to reduce this have high priority for the pharmaceutical industry. To this end, drug development and medicinal treatment need to be more personalized and molecular imaging techniques, in particular Positron Emission Tomography (PET) imaging, can be used to achieve this by 1) evaluating the effectiveness of new treatments emerging from the pharmaceutical industry, 2) improving the ability to diagnose diseases, and 3) aid tailoring the treatment based on individual patient pathology. A limiting factor to develop new effective PET imaging probes is the insufficient number of radiopharmaceutical scientists presently available. Our consortium has assembled 6 radiopharmaceutical frontline academic and 10 non-academic partners to address this problem and train the next generation of radiopharmaceutical scientists. Our training will be focused on an unmet scientific need for Parkinson’s Disease (PD). Fibril formation of protein α-synuclein is thought to be the hallmark for PD, but presently, there are no validated PET tracers available for visualization of pathogenic aggregates of this protein. Our scientific goal is to develop such tracer. A successful tracer will have a strong impact on PD-diagnosis and facilitate the development of effective disease modifying treatments. To reach our goals, it is necessary to train our early stage researchers in a highly interdisciplinary fashion spanning from chemistry, over biology, GMP and pharmacy to nuclear medicine. Furthermore, this consortium will train entrepreneurial skills and facilitate start up new enterprises in the current favorable radioisotope market situation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PET-ALPHASY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PET-ALPHASY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More